Compare HUMA & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUMA | VYGR |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United States |
| Employees | 220 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.4M | 194.0M |
| IPO Year | N/A | 2015 |
| Metric | HUMA | VYGR |
|---|---|---|
| Price | $0.68 | $3.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $9.29 | ★ $21.00 |
| AVG Volume (30 Days) | ★ 8.0M | 879.5K |
| Earning Date | 03-27-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,135,000.00 |
| Revenue This Year | N/A | $33.19 |
| Revenue Next Year | $731.05 | $14.68 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.70 | $2.65 |
| 52 Week High | $2.93 | $5.55 |
| Indicator | HUMA | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 31.26 | 48.26 |
| Support Level | N/A | $3.61 |
| Resistance Level | $1.30 | $4.43 |
| Average True Range (ATR) | 0.10 | 0.31 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 2.03 | 20.16 |
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.